BioCryst Pharmaceuticals Receives $19.64 Consensus Price Target

Analysts give BioCryst Pharmaceuticals a 'Moderate Buy' rating on average

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average recommendation of 'Moderate Buy' from the thirteen analysts currently covering the company. The average 12-month price target among brokers is $19.64.

Why it matters

BioCryst Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel, oral small-molecule medicines for rare and serious diseases. The consensus price target and 'Moderate Buy' rating from analysts suggest optimism about the company's future prospects and the potential of its drug pipeline.

The details

The analysts' recommendations range from one 'sell' rating, two 'hold' ratings, and ten 'buy' ratings. Needham & Company LLC reduced their price target on BioCryst from $20 to $18, while Evercore initiated coverage with an 'outperform' rating and $17 price target.

  • BioCryst Pharmaceuticals reported quarterly earnings on February 26, 2026.

The players

BioCryst Pharmaceuticals, Inc.

A clinical-stage biotechnology company headquartered in Durham, North Carolina that focuses on the discovery and development of novel, oral small-molecule medicines for rare and serious diseases.

Needham & Company LLC

An investment banking and asset management firm that reduced its price target on BioCryst Pharmaceuticals.

Evercore

An investment banking advisory firm that initiated coverage on BioCryst Pharmaceuticals with an 'outperform' rating and $17 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The consensus price target and 'Moderate Buy' rating from analysts suggest optimism about BioCryst Pharmaceuticals' future prospects and the potential of its drug pipeline, which focuses on developing novel treatments for rare and serious diseases.